Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 15

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 15
---
 of MIRA Common Stock as of the record date, and you are entitled to vote at the MIRA Annual Meeting to approve the matters described in this proxy statement. This proxy statement contains important information about the MIRA Annual Meeting, the Merger, the Merger Agreement and the other business to be considered by MIRA stockholders at the MIRA Annual Meeting and you should read it carefully and in its entirety. The enclosed voting materials allow you to authorize a proxy to vote your shares of MIRA Common Stock without attending the MIRA Annual Meeting. As promptly as practicable, please complete, sign, date and mail your proxy card in the pre-addressed postage-paid envelope provided or call the toll-free telephone number listed on your proxy card or access the internet website described in the instructions on the enclosed proxy card.

Q: What is required to consummate the Merger?

A:To consummate the Merger, the holders of MIRA Common Stock must approve the Merger Proposal. Proposal No. 2 is not a closing condition for the consummation of the Merger.

In addition to the requirement of obtaining stockholder approval of the Merger Proposal, each of the other closing conditions set forth in the Merger Agreement must be satisfied or, unless not waivable as a matter of law, waived. For a complete description of the closing conditions under the Merger Agreement, we urge you to read the section titled “ The Merger Agreement—Conditions to the Merger.”

Q: Will holders of the MIRA Common Stock issued in the Merger be able to sell those shares without restriction?

A:The shares of MIRA Common Stock issued as consideration in the Merger will be issued in transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”) in reliance on Section 4(a)(2) of the Securities Act and may not be offered or sold by the holders of those shares absent registration or an applicable exemption from the registration requirements. As a general matter, holders of such shares will not be able to transfer any of their shares until at least six months after receiving shares of MIRA Common Stock, which is when the shares would first be eligible to be sold under Rule 144 promulgated under the Securities Act, assuming the conditions thereof are otherwise satisfied.

Q: What will MIRA’s stockholders receive in the Merger?

A:At the Effective Time, MIRA’s stockholders will continue to own and hold their existing shares of MIRA Common Stock.

Q: What will